MedTrace Logo

Proof of Concept (POC) in Patients With Ischaemic Stroke

NCT01808261 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2017-11-17

Study results available
· View outcomes & findings →

Summary

Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients.

Conditions

  • Cerebrovascular Accident

Interventions

DRUG

GSK249320 100/mg

Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.

DRUG

Placebo

Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-18
Primary Completion
2014-07-28
Completion
2014-07-28

Countries

  • United States
  • Canada
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01808261 on ClinicalTrials.gov